Nexelis

Activities: Manufacturing Pharmaceutical

Trending Articles

  1. NHS, MHRA and Medicines UK launch Project Revive to tackle medicine shortages NHS England, the MHRA and Medicines UK have launched Project Revive, a collaborative pilot designed to address critical medicines shortages by fast-tracking dormant...
  2. Isopod Rapid Cleanrooms: the ideal elite controlled environment pod solution for Life Sciences and Engineering start-ups The Guardtech Group’s quick-assembly cleanroom pods combine superior performance, build quality and cost-effectiveness to give new applications the perfect platform to get...
  3. You need to be a subscriber to read this article.
    Click here to find out more.
    Delivering precision: why advanced therapies are redefining pharmaceutical logistics As advanced therapies narrow tolerances and personalise care, pharmaceutical logistics is being redefined as a precision-driven extension of treatment delivery, writes Michael...
  4. Nose-to-brain delivery outperforms systemic BBB technologies according to MetP Pharma The pioneering company has published preclinical data that strongly supports the advantages of its proprietary nose-to-brain drug delivery technology compared with systemic...
  5. AstraZeneca strengthens weight management pipeline with CSPC Pharmaceuticals collaboration The pair have signed a strategic collaboration covering eight obesity and type 2 diabetes programmes, including a clinical-ready GLP-1/GIP asset, AI-driven peptide discovery...

Upcoming event

High Shear = Mixing Success

19 February 2026 | Virtual See all

Related Content

Regulatory

Nexelis wins ViE award for central/specialty laboratory

The company’s VP Vaccine Sciences, Luc Gagnon, recently presented to the World Vaccine Congress alongside Valentina Bernasconi of CEPI
Ingredients

Why the production of bispecific antibodies depends on early stage product characterisation

Chloe Ackaert, Senior Scientist, and Sofie Pattijn, Chief Technology Officer and founder, ImmunXperts a Nexelis group company, explain how early development studies to evaluate functionality and immunogenicity help to derisk the manufacture of bispecific antibodies
Subscribe now